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 ABSTRACT 
 
The Effect of Aging and Resveratrol Supplementation on Bone Mass and 
Strength in Hindlimb Suspended Male Rats 
 
 
Stephanie Wright 
 
Resveratrol has recently become a popular dietary supplement because of 
its potential for reducing the effects of aging and various age-related diseases. 
However, few studies have investigated the role of resveratrol in improving bone 
loss associated with aging.  It has been widely reported that mechanical unloading 
increases bone loss.  The elderly experience a prevalence of reduced mechanical 
loading due to declining activity levels and increased incidence of bed rest.  In 
rats, hind-limb suspension (HLS) simulates mechanical unloading of bone.  
Therefore, the objective of this study was to examine the effects of aging and 
resveratrol supplementation on bone health in HLS and ambulatory (AMB) rats. 
 
Mature (age 6 months) and old (32 months) Fischer Brown Norway male 
rats were randomly assigned (n=7/group) to HLS or kept ambulatory (AMB) for 
14 days and received either 1 ml of trans- resveratrol at a dose of 12.5  
mg·kg bw
-1
·d
-1
 or deionized water administered by oral gavage.  After 14 days, 
both femurs and tibiae were collected.  Bone mineralization was measured by 
dual energy x-ray absorptiometry (DEXA).  Bone calcium (Ca) and phosphorus 
(P) were determined by inductively coupled plasma spectrophotometry. Bone 
architecture was determined using micro-computed tomography (µCT).  
Oxidation was determined by measuring plasma thiobarbituric acid reactive 
substances (TBARS) by enzyme immunoassay (EIA).  Inflammation was 
determined by measuring C-reactive protein (CRP) by ELIZA. 
 
Results showed that aging increased plasma CRP and reduced trabecular 
bone (P<0.001).  In old AMB rats, resveratrol supplementation increased 
trabecular thickness (P=0.018), but decreased tibia bone mineral area (P=0.031) 
and bone mineral content (P=0.034).  In old HLS rats, resveratrol 
supplementation increased trabecular bone (P<0.001) and reduced oxidation 
indicated by decreased plasma TBARS (P<0.05) compared to rats not provided 
resveratrol. In mature HLS rats resveratrol supplementation reduced bone Ca 
(P=0.018) and P (P=0.024) content.  TBARS were increased compared to rats 
provided no resveratrol.  In conclusion resveratrol supplementation attenuated 
trabecular loss but was not effective at attenuating bone mineral loss associated 
with aging.  In mature HLS rats resveratrol supplementation increased plasma 
oxidation and reduced bone Ca and P content.  Therefore, resveratrol is not 
recommended as a treatment for age-related bone loss. 
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1.0 INTRODUCTION 
Polyphenols are compounds produced by plants to protect against insects, 
microbes, and disease.  These compounds have been used in pharmaceuticals 
dating back to ancient times.  Currently, a polyphenol of interest is resveratrol, a 
trans-3, 4, 4‟-trihydroxystilbene structure. Resveratrol is found in various foods 
such as blueberries, peanuts, and mulberries (Vidavalur et al., 2006), but is 
particularly rich in the skin of red grapes.  The popularity of resveratrol over the 
past two decades is partially due to the “French paradox.”  In the French 
population prevalence of heart disease is low despite high consumption of 
saturated fats.  It was proposed that this reduction in heart disease was due to an 
increased intake of red wine (Kopp, 1998).  This led to research regarding 
resveratrol as the constituent of red wine responsible for health benefits.   
The health benefits of resveratrol have been attributed to its antioxidant 
and anti-inflammatory properties.  Resveratrol has been shown to reduce oxygen-
derived free radicals in vitro (Pervaiz, 2003).  In addition, in vitro studies have 
shown that resveratrol reduced pro-inflammatory eicosanoids, indicating anti-
inflammatory properties (Martinez and Moreno, 2000).   Due to antioxidant 
and/or anti-inflammatory properties, resveratrol has been studied for its roles in 
reducing the effects of aging.  Bone loss leading to osteoporosis is often 
associated with aging.  Research on resveratrol as a dietary supplement for 
reducing bone loss has been increasing; however, most studies have been in vitro.  
Few studies in vivo have investigated the role of resveratrol in preventing bone 
loss associated with aging.  
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Rats are often used as an animal model to study bone loss in humans. 
Male osteoporosis is typically an age-related disorder, developing after the age of 
60 (Raisz, 2005).  Therefore, the use of an appropriate aged male rat model is 
important in order to investigate age-related bone loss in males.  Bone growth 
begins to slow in male rats at maturity (age six months) (Wang et al., 2001).  At 
age nine months, male rats begin to lose bone similar to men age 60 or older (Jee 
and Ma, 1999).  Therefore, the use of age six-month-old and older rats provide an 
appropriate animal model of bone loss. 
In addition to age-related bone loss, the elderly experience declining 
activity levels and increased incidence of bed rest.  This results in reduced 
mechanical load which is associated with lower bone mineral density (BMD) 
(Magnus et al., 2008).   In rats, hindlimb suspension (HLS) has been used to 
simulate the effects of inactivity or bed rest.  HLS involves suspending rats from 
the tail to unload weight from the hindlimbs while allowing the forelimbs to move 
freely (Vico et al., 1995). 
More than 40 million Americans over the age of 50 have either reduced 
BMD or osteoporosis (Gronholz, 2008).
  
In the absence of a cure for bone loss 
leading to osteoporosis, emphasis is placed on prevention.  Oxidative stress has 
been associated with reduced BMD (Basu et al., 2001).  Antioxidants such as 
vitamin E have been reported to be bone protective in young (3 month old) 
nicotine withdrawn rats
 
(Hermizi and Faizah, 2009), and mature (8.5 month old) 
hindlimb suspended rats (Smith et al., 2005).  In these studies, vitamin E was 
shown to protect bone weight, mineralization, and strength.  Vitamin E may also 
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affect bone by inhibiting the enzyme cycloxygenase 2 (COX-2) and decreasing 
the prostaglandin (PG), PGE2 (Smith et al., 2005).  In vitro, PGE2 increased bone 
resorption by promoting osteoclast formation (Klein and Raisz, 1970).  Studies in 
mice and
 
humans also provided evidence that PGE2 enhances bone resorption 
(Norrdin et al., 1990).  Therefore, resveratrol may provide a dietary supplement 
for reducing bone loss due to its antioxidant and anti-inflammatory properties. 
The objective of the proposed study is to determine the effects of 
resveratrol supplementation on bone mineralization and strength in ambulatory or 
hindlimb suspended mature and old male rats.  To our knowledge the proposed 
study is the first to investigate the effects of resveratrol supplementation of aging 
male rats on bone.  The study results are expected to contribute knowledge 
towards developing dietary recommendations to reduce age-related bone loss 
leading to osteoporosis. 
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2.0. STUDY OBJECTIVES 
Hypothesis 
Resveratrol supplementation will positively affect bone mass, bone mineral 
content, and bone mineral density leading to increased  bone strength when 
consumed by mature and old, ambulatory and HLS rats 
To test this hypothesis, the study objectives were: 
 
Objective 1: To determine the effects of resveratrol supplementation on bone 
mass and bone strength in mature and old male rats. 
 
Objective 2: To determine the effects of resveratrol supplementation and 
hindlimb suspension on bone mass and bone strength in mature and old male rats. 
 
Objective 3: To determine potential mechanisms of actions of resveratrol on 
bone. 
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3.0. LITERATURE REVIEW 
3.1. Osteoporosis 
 Osteoporosis is a condition that is characterized by a decrease in bone 
mass due to decreased bone mineral density (BMD) and bone matrix (Kiebzak et 
al., 2002).  Reduced BMD and bone architecture results in bone fracture with 
minimal trauma.  Bone fractures usually occur at the hip, specifically the femoral 
neck.  After sustaining a hip fracture, only 15% of patients are able to return to 
unassisted ambulation within six months, and almost one in four hip-fracture 
patients will die within a year (Reginster and Burlet, 2006).  More than 40 million 
Americans over the age of 50 have either osteoporosis or low BMD.  
Approximately13 million are males (Gronholz, 2008).  However, most studies of 
osteoporosis have focused on post-menopausal women.  Only 4.5% of men with 
hip fractures receive treatment for osteoporosis compared to 27% of women 
(Gruntmanis, 2007).  Therefore, it is also important to study osteoporosis in 
males. 
In the absence of a cure for bone loss leading to osteoporosis, it is 
important to identify modifiable factors such as diet and exercise to prevent bone 
loss.  Nutrition and exercises that increase bone formation and reduce bone 
resorption may reduce the risk of osteoporosis.  The next sections discuss bone 
biology and bone turnover. 
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3.2. Bone Biology 
The two basic types of bone are cortical (compact) and trabecular (spongy) 
bone (Figure 1). Cortical bone provides support for the body and storage of 
minerals.  Cortical bone makes up the shaft of the long bones and constitutes 
approximately 85% of the total bone in the body.  Trabecular or cancellous bone 
has a sponge-like structure that provides a large surface area for mineral storage.  
Cancellous bone makes up the internal parts of the bone and typically occurs at the 
ends of the long bones.  Cancellous bone also provides the sites for bone forming 
cells.   
During aging, cortical and cancellous bone changes differ with loss of 
trabecular bone occurring earlier (Mundy, 1993).  Therefore, it is important to 
measure loss of the different types bone when studying osteoporosis.  Cortical 
mineralization can be determined using dual energy X-ray absorptiometry 
(DEXA).  Measurements include bone mineral area (BMA), bone mineral content 
(BMC) and bone mineral density (BMD).  BMA represents the area of bone 
occupied by minerals. BMC represents the mass of the bone, and BMD is a 
measurement of the bone mass per cm
2
 (Mazess et al., 1990.)   
Trabecular architecture can be determined using micro-computed 
tomography (μCT). Measurements of trabecular architecture include bone volume 
to total tissue volume ratio (BV/TV), trabecular number (TbN), trabecular 
separation (TbSp), trabecular thickness (TbTh), Structure Model Index (SMI), and 
connectivity density (CONN).  BV/TV represents the fraction of bone in the 
sample. TbN is the number of trabulae per mm bone.  TbSp corresponds to the 
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mean size of the intertrabecular spaces.  TbTh represents the mean diameter of the 
trabeculae.  SMI characterizes the type of structure of the sample (rod-like, plate-
like or mixed structures), and CONN is a quantified measurement of elasticity 
(Peyrin et al., 1998).  Loss of trabecular and cortical bone is linked to increased 
bone turnover.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Biology of bone structure, adapted from Spence A, 1990. 
 
3.3. Bone Turnover 
Bone turnover is a process by which old bone is broken down (resorption) 
and new bone is formed (deposition).  The cells responsible for bone deposition 
are osteoblasts; whereas, the cells responsible for resorption are osteoclasts.  As 
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illustrated in Figure 2, remodeling starts with the activation of hematopoietic 
precursors to become osteoclasts that promote bone resorption.  Activation of 
osteoclasts can be initiated by inflammatory cells.  Following bone resorption, 
osteoclasts signal osteoblasts to begin forming bone matrix and to deposit 
minerals.  Alkaline phosphatase (ALP) is associated with bone matrix synthesis 
prior to mineralization (Cao et al., 2009).  Therefore, plasma ALP has been used 
as an indicator of bone formation.  
Bone is constantly being remodeled throughout adult life resulting in the 
removal of old bone (resorption) and replacement by new bone (deposition).  In 
general, the processes of bone resorption and formation are "coupled" so that 
there is no net change in bone mass.  During aging bone resorption exceeds bone 
formation leading to a net increase in bone loss.  In humans, bone mass and 
strength are obtained from approximately age 15 to the mid-thirties (Gruntmanis, 
2007).  Unlike in humans, in rats the epiphyses do not fuse resulting in bone 
growth up to old age (Dawson, 1925).  To study age-related bone loss, the use of 
appropriate aged male rat model is important.  Wang et al. (2001) reported that 
proximal tibia and femoral neck bone mineral accrual slowed at age six months, 
and bone loss began at age nine months in male Sprague-Dawley rats.  Therefore, 
in rat models it is important to include bone morphometry measurements of 
length, width, depth, and weight even in aging rats (Jee and Ma, 1999).  Loss of 
bone mineral and matrix results in reduced bone strength and in turn, increased 
risk of bone fracture.  The next section discusses bone biomechanical strength 
measurements. 
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Figure 2. Bone Turnover 
 
 
 
 
 
 
 
 
 
3.4. Bone Biomechanics 
Biomechanical properties can determine bone susceptibility to fractures. 
Bone fractures occur as a result of different etiologies; therefore, several different 
biomechanical measurements define bone fragility.  Biomechanical indices of 
bone fragility include: strength, brittleness, and work to failure and stiffness 
which is also used to assess mechanical integrity of the bone (Turner, 2002).  
These indices are derived from a biomechanical test in which force is applied to a 
bone until it breaks.  A force-displacement curve (Figure 3) is generated from the 
biomechanical test.  Bone strength (ultimate force) is defined as the height of the 
curve.  Work to failure is defined as the area under the curve and brittleness is 
estimated from the reciprocal of the curve (Turner, 2002).  Ultimate bending 
stress and Young‟s modulus are also biomechanical measurements used to 
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determine bone properties.  Ultimate bending stress is a normalized calculated 
force that takes into account the size of the bone, and Young‟s modulus is 
normalized stiffness that takes into account bone size (Yuan and Kitts, 1992). 
 
Figure 3. A force-displacement curve resulting from a biomechanical test of a 
bone specimen.  The height of curve represents ultimate force (Fu), area under the 
curve (U) represents work to failure energy, the slope of the curve is the stiffness 
(S) and the width of the curve is the ultimate displacement (du). (Turner, 2002) 
 
Aging is associated with a number of conditions with the potential to 
accelerate bone loss such as: chronic inflammation, increased free radicals, and 
reduced physical activity.  The next sections examine the effect of these factors on 
bone. 
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3.5. Inflammation and Bone 
 Inflammation is an immune response to injury or infection.  C-reactive 
protein (CRP) is a substance secreted by the liver during acute inflammation.  
Higher serum levels of CRP are associated with lower BMD in older adults.  Ding 
et al. (2007) reported that high-sensitivity (hs)-CRP was inversely associated with 
total body BMD in men and women (age 52-78).  Additionally, hs-CRP was 
positivity associated with urinary pyridinoline, a marker for bone resorption. 
Inflammatory compounds also include eicosanoids derived from fatty 
acids.  Cyclooxygenases (COX) enzymes mediate the production of a class of 
eicosanoids called prostaglandins (PGs).  Prostaglandin E2 (PGE2) derived from 
conversion of the fatty acid arachidonic acid (20:4 n-6) by COX-2, has been 
shown to stimulate both osteoclast and osteoblast formation
 
(Klein and Raisz, 
1970).
  
PGE2 released from osteoblasts promotes the formation of osteoclasts for 
bone remodeling (Norrdin et al., 1990).  Chronic overproduction of PGE2 results 
in increased bone resorption (Klein and Raisz, 1970). COX-1 and COX-2 
inhibitors such as non-steroidal anti-inflammatory drugs (NSAIDS) have been 
shown to decrease inflammation markers as well as reduce bone resorption by 
inhibiting osteoclast formation in vitro
 
(Raisz, 2001).  In addition, 
epidemiological studies show that patients who take aspirin have slightly higher 
(P<0.05) bone mass at the femoral neck and lumbar spine compared to age-
matched patients not taking aspirin
 
(Bauer et al., 1996). 
Other inflammatory mediators associated with bone metabolism are 
cytokines.  Cytokines have been shown to stimulate osteoclast formation in vitro 
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and in vivo (Manolagas and Jilka, 1995), and to inhibit osteoblast differentiation 
in vitro (Gilbert et al., 2000).  In addition, higher levels of serum CRP and 
cytokines in elderly (age70-79) men and women are associated with increased 
risk of bone fracture (Cauley et al., 2007). 
During chronic states of inflammation, increased expression of 
inflammatory cytokines recurrently activates macrophages which in turn produce 
more inflammatory cytokines (Feghali and Wright, 1997).  Perpetual cytokine 
articulation amplifies osteoclast formation and bone resorption (Mundy, 1993).  In 
addition to inflammation, aging also increases generation of free radicals.  Recent 
studies have suggested a role of increased free radicals in bone loss. 
 
3.6. Oxidative Stress and Bone 
 Free radicals are molecules that have an unpaired electron.  As a result, 
free radicals are highly reactive and may cause damage (oxidation).  Excessive 
production of free radicals with insufficient antioxidants results in oxidative 
stress.  Oxidative stress has been linked with aging and increased risk of 
degenerative diseases including osteoporosis (Basu et al., 2001). 
 Cell cultures of mouse frontal and parietal bones and of rat radii and ulnae 
were shown to release calcium (Ca) into media when exposed to superoxide 
anions (O
2-
), hydrogen peroxide (H2O2),  or hydroxyl radicals (OH·).  The authors 
suggested that release of Ca indicated increased bone resorption.  The antioxidant 
enzyme superoxide dismutase (SOD) was added at a dose of 6μM to bone cell 
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culture.  Bone resorption measured by the percentage of total Ca released into 
media was inhibited by SOD (Garret et al., 1990).   
 In a study using 48 women and 53 men (age 22-85 years) the biomarker of 
oxidation, urinary 8-iso-PGF2  was measured to determine the association of 
oxidation to BMD at the lumbar spine, femoral hip and total body.  Higher 8-iso-
PGF2  levels were associated with lower BMD, specifically at the lumbar spine 
and total body, indicating a negative relationship between oxidation and BMD 
(Basu et al., 2001).  The importance of antioxidants in reducing risk of 
osteoporosis was demonstrated in a study showing that men and women with 
osteoporosis (n=50) had lower (P< 0.05) activity of the endogenous antioxidant 
glutathione peroxidase (GPx) than subjects without osteoporosis (n=44).  In 
addition, higher GPx was positively correlated (r=0.31, P<0.001) to heel BMD 
measured by dual energy x-ray absorptiometry (DEXA) (Sanchez-Rodriguez et 
al., 2007).  Chronic inflammation and oxidative stress have been shown to be 
detrimental to bone.  Therefore, it is important to discuss strategies for reducing 
inflammation and/or oxidative stress to prevent bone loss. 
 
3.7. Antioxidants and/or Anti-inflammatory Compounds in the Prevention of 
Bone Loss 
In a human study, postmenopausal women age 50-98 years who were 
provided with vitamin C at supplemental doses of 100 to 5,000 mg/d for 12 years 
had higher (P=0.02) BMD at the femoral neck compared to women not receiving 
vitamin C supplements (Morton et al., 2001).  Osteoblast cells grown in media 
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containing 50 µg/ml of the antioxidant vitamin, ascorbic acid (vitamin C) for 24-
48 hours increased osteoblast differentiation and ALP mRNA expression.  The 
results suggested that antioxidants promote bone health by promoting osteoblastic 
deposition (Franceschi et al., 1994).   
Another antioxidant vitamin, tocopherol (vitamin E) also has anti-
inflammatory properties.  In an animal study, young (3 month old) nicotine 
withdrawn male Sprague-Dawley rats provided vitamin E supplementation (60 
mg/kg body weight/day) for 8 weeks had increased bone mass and mineralization. 
Increased bone mineralization was indicated by histological measurements of 
increased bone volume normalized to tissue volume (BV/TV), mineral apposition 
rate (MAR), and bone formation rate normalized to bone volume (BFR/BV) 
(Hermizi and Faizah, 2009).  Vitamin E may decrease bone resorption by 
inhibiting the enzyme COX-2 and decreasing serum PGE2
 
(Smith et al., 2005). 
Numerous polyphenols existing in fruits and vegetables have been shown 
to have both anti-inflammatory and antioxidant properties (Habauzit and 
Horcajada, 2008).  Epigallocatechin-3-gallate (EGCG), a phenolic compound in 
green tea, has been shown in vitro to inhibit osteoclast formation and activity by 
reducing free radical production (Habauzit and Horcaja, 2008).  Flavonoids (i.e. 
quercetin and kaempferol) found in red apples have been shown to inhibit COX-2 
and to suppress osteoclast differentiation and bone resorption in vitro (Wattel et 
al., 2003).  Dried plum polyphenols have been shown to decrease COX-2 and 
cytokine expression (Bu et al., 2008).  Osteoblasts grown in media containing 10, 
20, or 30 µg/mL dried plum polyphenols, chlorogenic acid and caffeic acid 
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showed decreased osteoclast differentiation and oxidative stress under normal and 
inflammatory states.  Resveratrol, a polyphenolic compound, may have beneficial 
health effects due to antioxidant and anti-inflammatory properties.  However, few 
studies have investigated the effect of resveratrol on bone, particularly in vivo. 
 
3.8. Resveratrol 
Resveratrol is a 3, 4, 4‟-trihydroxystilbene structure consisting of two 
phenol rings linked by a styrene double bond.  This double bond facilitates the 
formation of two isomeric forms.  The trans structure is more abundant, but it 
transforms into the cis form when exposed to ultraviolet light (Figure 4).  In 
addition being classified as a polyphenol, resveratrol may also be categorized as a 
phytosterol, phytoestrogen, and phytoalexin. 
Resveratrol is produced by plants such as red grapes, eucalyptus, spruce 
trees, certain species of lilies, peanuts, blueberries, and mulberries upon exposure 
to fungal infection, insects, or microbes.  Resveratrol is produced as a defense 
mechanism against external toxins and therefore, is most abundant in the outer 
layer of the plants (Pervaiz, 2003).  
 In vivo studies reported 38% bioavailability when resveratrol was orally 
administered to male Sprague-Dawley rats (Marier et al., 2002).  In humans, 
approximately 70% of orally administered resveratrol is absorbed
 
(Goswami and 
Das, 2009).  Following absorption in the small intestines, resveratrol enters the 
hepatic portal vein and is glucuronidated in the liver.  Both trans- and cis-
resveratrol undergo enterohepatic recirculation and then enter the bloodstream 
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after a period of 4 to 8 hours (Marier et al., 2002).  In the circulation resveratrol 
binds to lipoproteins and albumin, and its cellular uptake is carrier mediated
 
(Goswami and Das, 2009).  Over 99% of absorbed resveratrol is distributed to 
tissues.  Less than 0.15% of absorbed resveratrol is excreted in the urine
 
(Marier 
et al., 2002).  In the body, resveratrol has been reported to have various beneficial 
effects. 
 Resveratrol has been widely investigated as an antioxidant (Leonard et al., 
2003).  In addition, resveratrol is capable of reducing inflammation (Pervaiz, 
2003).  As an anti-inflammatory compound, resveratrol‟s main mode of action is 
the suppression of COX enzymes which mediate the production of a class of 
eicosanoids called prostaglandins (PGs).  Resveratrol supplementation at doses of 
0.10-10 µM has been shown to decrease the production of PGE2 by osteoblasts in 
vitro by approximately 30% (Mizutani et al., 1998).  Since PGE2 released from 
osteoblasts promotes the formation of osteoclasts, resveratrol may reduce 
osteoclast resorption of bone by reducing PGE2 production. 
In cell culture studies, resveratrol has been shown to influence osteoblasts 
and osteoclasts.  Resveratrol supplementation at doses of 25-100 µM
 
has been 
shown to decrease osteoclast differentiation (Boissy et al., 2005) and to promote 
osteoblast differentiation at doses of 0.10-100 µM (Dai et al., 2007).  
Most research investigating the effect of resveratrol supplementation on 
bone has been conducted in vitro.  Few studies have investigated the effect of 
resveratrol supplementation on bone health in vivo.  Young (age 3 months) 
ovariectomized Sprague-Dawley rats provided resveratrol at a dose of 45 mg/kg 
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body weight/day for 13 weeks resulted in  protection against ovariectomy induced 
BMD loss at the lumbar spine and femur (Lin et al., 2005).  Low dose resveratrol 
supplementation (0.7 mg/kg body weight/day) in young ovariectomized Sprague-
Dawley rats for 12 weeks resulted in increased BMD and bone Ca content (Liu, et 
al., 2005).  In addition, resveratrol supplementation in mature (aged 5 months) 
ovariectomized spontaneously hypertensive rats at a dose of 0.5 mg/kg body 
weight/day for just 3 weeks reduced ovariectomy induced loss of femur strength 
without affecting calcium and phosphorus content (Mizutani et al., 2000).  To our 
knowledge no studies have investigated the potential effect of dietary resveratrol 
supplementation on age-related bone loss in male rats. 
 Figure 4. Resveratrol 
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3.9. Mechanical Unloading of Bone 
It is well-established that mechanical unloading such as decreased 
physical activity and bed rest accelerates bone loss due to increased resorption 
(LeBlanc et al., 2005).  Exercise has been shown to help protect against bone loss.  
However, individuals over the age of 50 are a population already at high risk for 
bone loss and are also the most sedentary adults
 
(King et al., 1998).  During their 
lifetime, half of all women and one-third of all men will suffer a bone fracture
 
(Magnus et al., 2008).  Only 15% of hip fracture patients are able to return to 
unassisted ambulation after 6 months
 
(Reginster and Burlet, 2006).  Furthermore, 
decreased activity in hip fracture patients increases subsequent bone fracture due 
to loss of skeletal integrity. 
Hindlimb suspension (HLS) has been used in rats to model the effects of 
mechanical unloading on bones.  In HLS, the rat is suspended from its tail to 
mechanically unload the hindlimbs while allowing the forelimbs to move freely
 
(Figure 5).  HLS for two weeks has been shown to promote bone loss.  
Administration of vitamin E to mature (8.5 month old) hindlimb suspended male 
Sprague-Dawley rats has been shown be bone protective.  Vitamin E 
supplementation at a dose of 500 IU/kg diet for 9 weeks increased bone mass 
indicated by increased bone surface normalized to tissue volume (BS/TV) by 
acting as an antioxidant.   
Resveratrol has antioxidant properties, but to our knowledge no studies 
have investigated the effect of dietary resveratrol supplementation on bone in 
HLS rats. Few studies have investigated the role of resveratrol in improving bone 
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loss associated with aging, and to our knowledge no studies have investigated 
effects of resveratrol on bones in male rats. 
Figure 5. Hindlimb Suspension Apparatus 
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4.0 MATERIALS AND METHODS 
4.1. Animal Feeding Study 
 All animal procedures were approved by the Animal Care and Use 
Committee at West Virginia University and were conducted in accordance with 
the guidelines set forth by the Institute of Laboratory Animal Resources 
Commission on Life Sciences for the Care and Use of Laboratory Animals 
(1996).  Upon arrival in the animal care facilities, mature (6 months) and old (32 
months) male Fischer Brown Norway rats (n=56) were individually caged and 
kept in rooms maintained at 22 +2
o
C with a 12:12 h light/dark cycle (6:00 am 
light on/6:00 pm lights off).  Rats were provided with water and standard rat chow 
(Formlab 5008, PMI Feeds Inc, Richmond, IN) ad libitum throughout the 14 d 
study. 
In Study 1 the effect of resveratrol supplementation at different ages on 
bone was determined.  Mature (6 months) and old (32 months) rats were 
acclimated for 7 days.  Following 7 day acclimation, mature and old rats were 
randomly assigned (n=7/group) to receive 1 ml of trans-resveratrol suspended in 
1 milliliter of 0.1% carboxymethylcellulose (CME) or vehicle consisting of 1 ml 
deionized water dissolved in 0.1% CME (control).  The treatment solutions were 
administered at a dose of 12.5 mg·kg bw
-1
·d
-1
 by daily oral gavage for 14 d.   
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The treatment groups were:   
1) Mature control rats (MC) 
2) Mature resveratrol rats (MR) 
3) Old control rats (OC) 
4) Old resveratrol rats (OR) 
 
In Study 2 mechanical unloading of bone was investigated because aging 
is often accompanied by reduced physical activity and bed rest.  Mature (6 
months) and old (32 months) male Fischer Brown Norway rats were hindlimb 
suspended (HLS) according to Morey-Holton and Globus (2002)
 
as shown in 
Figure 3.  The individually housed rat was suspended by its tail.  This allowed 
unloading of weight from the hindlimbs while allowing free ambulation of the 
forelimbs.  This provided rats with 360° movement around the cage and free 
access to diet and water.  Rats were HLS for 14 d.  HLS for 14 d is the minimal 
time shown to produce bone loss (Vico et al., 1995). 
Similar to study 1, following a 7 d acclimation, the mature and old HLS 
rats were randomly assigned (n=7/group) to receive 1 ml of trans-resveratrol 
suspended in 1 milliliter of 0.1% CME or vehicle consisting of 1 ml deionized 
water dissolved in 0.1% CME (control).  The treatment solutions were 
administered at a dose of 12.5mg/kg body weight/d by daily oral gavage for 14 d. 
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Treatment groups were:   
1) Mature hindlimb control rats (MHC)   
2) Mature hindlimb resveratrol rats (MHR)  
3) Old hindlimb control rats (OHC)   
4) Old hindlimb resveratrol rats (OHR) 
   
In Study 1 and 2, rats were euthanized after 14 d with a mixture of 5% 
isoflourane and 95% oxygen using a small animal anesthetic system (Isotec 5, 
Ohmeda) at the end of the 14 d. The right and left femur and tibia were collected 
and stored at -20
o
C until used for bone measurements.  The femur and tibia were 
examined because Lafage-Proust et al. (1998)
 
reported that in rats the femur was a 
slower maturing bone than the tibia and, therefore, more sensitive to unloading. 
 
 4.2. Bone Morphometry 
The bones were brought to room temperature and carefully defleshed 
without damaging the periosteum.  Each bone was individually wrapped in 
deionized distilled water-soaked gauze and stored at –20oC until analysis.  To 
determine bone morphometry, bones were brought to room temperature and 
weighed.  Bones were weighed using an analytical balance (A-200DS, Fisher 
Scientific).  Bone length, width, and depth were determined using a vernier 
caliper (Bel-Art Products, Pequannock, NJ).  Length was measured from medial 
condyle to greater trochanter.  Diameter was measured at mid-section of shaft 
from lateral to medial end i.e. diaphysis. 
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4.3. Bone Biomechanics 
Bone strength parameters were assessed using a TA.HDi Texture Analyzer 
(Texture Technologies Corp, NY) outfitted with a three-point bending apparatus.  
The right and left femora and tibiae were placed on supports and bent until broken 
by lowering a centrally placed blade at constant crosshead speed (2 mm/s) and 
load cell of 250 kg.  A PC interfaced with the Texture Analyzer was used to 
collect data for determination of bone strength measurements of peak force, 
ultimate stiffness, ultimate bending stress (UBS), and Young‟s modulus as 
described by Yuan et al. (1992)  The bone biomechanical forces were calculated 
as: 
1) Peak force (N): the maximum force obtained during the bending procedure 
resulting in the initiation of the bone breaking 
2) Ultimate stiffness (N/s): the slope of the time-force deformation curve 
3) Ultimate bending stress (UBS, N/mm2): a normalized, calculated force 
that takes into consideration the size of the bone calculated as:       
UBS =           8 × peak force ×L × a1 
                                           _____________________        
                                                    Л ((a1
3
a2)-(b1
3
b2))     
 
Where L is the distance between the supporting points (10 mm); a1= the 
outer diameter in the direction of the load, a2= the outer diameter at right 
angles to a1, b1=the inner diameter in the load direction and b2=the inner 
diameter at right angles to b1.  
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4) Young‟s Modulus (YM, N/mm2): a normalized calculated stiffness that 
takes into consideration the size of the bone calculated as: 
Young‟s Modulus =           4× L3× ultimate stiffness (slope) 
                                                           ____________________________ 
 
                                                                       3× Л ((a1
3
a2)-(b1
3
b2)) 
  
Where L=the distance between the two edges in the three-point bending 
(10 mm), a1= the outer diameter in the direction of the load, a2= the outer 
diameter at right angles to a1, b1=the inner diameter in the load direction 
and b2=the inner diameter at right angles to b1. 
 
4.4. Bone Mineral Density and Content 
The left bones were packed on dry ice and shipped overnight to Oklahoma 
State University.  Dual energy X-ray absorptiometry (DEXA) scans (Hologic 
QDR 4500-A Elite) were performed on excised tibial and femoral specimens 
placed in Millipore water.  Bone mineral area (BMA), bone mineral content 
(BMC), and bone mineral density (BMD) were evaluated from all scans using the 
Regional High Resolution software package designed for studying isolated bone 
specimens (Hologic Waltham, MA). 
To assess bone architecture, the femur and tibia were scanned using µCT 
(MicroCT40, SCANCO Medical, Switzerland). The distal femur metaphysis and 
proximal tibial metaphysis were scanned and 200 images (~16 µm/slice or 3.2 
mm) were analyzed by semi-automatically placing contours beginning 25 slices 
(400 µm) away from the growth plate and included only secondary spongiosa 
25 
 
within the volume of interest (VOI). All scans were performed utilizing a 1024 x 
1024 matrix resulting in an isotropic voxel resolution of 22 μm3. An integration 
time of 70 milliseconds per projection was used with a rotational step of 0.36 
degrees resulting in total acquisition time of approximately 150 minutes/sample. 
The VOI was assessed for structural parameters including trabecular bone volume 
per unit of total volume (BV/TV), trabecular number (TbN), trabecular thickness 
(TbTh), trabecular separation (TbSp), structure model index (SMI) and 
connectivity density (CONN). 
 
4.5. Bone Ash, Calcium, and Phosphorus 
The femur and the tibia were dried at 110ºC for 24 h to determine dry 
weights.  Total bone ash content of the femur and of the tibia was determined by 
ashing the dried bones at 600°C in a muffle furnace (model 19.2A, Fisher 
Scientific) for 24 hours.  Total bone ash was determined by weighing the bone 
ash.  To determine bone calcium (Ca) and phosphorous (P) content, ashed 
samples were dissolved in 2 mL of 70% nitric acid.  The acidified samples were 
neutralized in 5 ml deionized distilled water (ddH2O) and filtered through 
Whatman no. 1 paper.  Samples were diluted to volume with ddH2O (500 mL).  
Femur and tibia Ca and P concentrations were determined by inductively coupled 
plasma optical emission spectrophotometry (model P400, Perkin Elmer, Shelton, 
CN).   
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4.6. Plasma Alkaline Phosphatase 
Plasma alkaline phosphatase (ALP) was measured as an indicator of 
osteoblast activity i.e. bone formation.  ALP was determined by enzymatic 
reactions that produced a color changes using a vet 16 rotor Hemagen Analyst 
(Hemagen Diagnostics, Inc. Columbia, MD).  The rotors were read using the 
Hemagen Analyst automated spectrophotometer (Hemagen Diagnostics, Inc. 
Columbia, MD). 
 
4.7. Plasma Calcium and Phosphorus 
Rats were euthanized with isoflurane and blood samples obtained by 
cardiac puncture.  Blood samples collected in tubes containing heparin were then 
centrifuged at 1,500 g for 10 min at 4
o
C to separate plasma.  Plasma samples were 
collected and stored at –80oC until assayed.  Plasma calcium and phosphorus were 
determined by enzymatic reactions that produced a color changes using a vet 16 
rotor Hemagen Analyst (Hemagen Diagnostics, Inc. Columbia, MD).  The rotors 
were read using the Hemagen Analyst automated spectrophotometer (Hemagen 
Diagnostics, Inc. Columbia, MD). 
 
4.8. Oxidative Stress  
Oxidative stress was determined using a Thiobarbituric Acid Reactive 
Substances (TBARS) assay.  TBARS were performed according to Cayman‟s 
TBARS Assay (Cayman Chemical, Ann Arbor, MI).  Plasma samples were mixed 
with sodium dodecyl sulfate (SDS) solution and a color reagent containing TBA, 
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acetic acid, and sodium hydroxide.  Samples were incubated for 60 minutes in a 
90ºC water bath and then incubated in an ice bath for 10 minutes to stop the 
reaction.  Following centrifugation for 10 minutes at 1,600 x g at 4ºC, samples 
were measured.  Absorbance was read at 540 nm using a Spectramax Plus 
microplate reader (Molecular Devices, CA) with values expressed as µM/MDA 
(malondialdehyde). 
Plasma total antioxidant capacity was measured using Cayman‟s 
Antioxidant Assay (Cayman Chemical, Ann Arbor, MI).  Plasma samples were 
diluted with 5 mM potassium phosphate buffer, containing 0.9% sodium chloride 
and 0.1%  glucose, at a pH of 7.4 (1:24 v/v).  6-Hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid (Trolox), was added to standard wells 
while diluted samples were added in duplicate to sample wells.  Metmyoglobin 
and 2,2‟-Azino-di-[3-ethylbenzthiazoline sulphonate] (ABTS) were added to all 
wells.  Hydrogen pyroxide was then added to initiate the reaction.  Samples were 
covered and incubated at room temperature on a shaker for 5 minutes.  
Absorbance was read at 750 nm using a Spectramax Plus microplate reader 
(Molecular Devices, CA).  Antioxidant concentration was expressed as 
mM/Trolox. 
 
4.9. Plasma C-reactive Protein 
C-reactive protein (CRP) was measured to determine acute inflammation 
using a Helica™ C-reactive protein assay.  Plasma samples were diluted to 
1:4,000 and allowed to react with antibodies coated on specially treated 
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microwells.  After 30 minutes incubation, the wells were washed to remove 
unreacted serum proteins, and an enzyme-labeled rabbit anti-rat CRP (conjugate) 
was added to label the antigen-antibody complexes.  Following another 30 minute 
incubation period, the wells were washed again to remove unreacted conjugate.  A 
urea peroxide substrate with 3,3‟, 5,5‟-tetramethylbenzidine (TMB) as chromogen 
was added to start color development.  Stop solution was added after 5-10 minutes 
to interrupt the reaction.  Absorbance was read at 450 nm using a Spectramax 
Plus microplate reader (Molecular Devices, CA) with values expressed as mg/ml.  
 
4.10. Statistical Analysis 
Data are expressed as mean ± standard error of the mean (SEM).  A two-
way ANOVA was used to determine the effect of age, treatment, or age x 
treatment on measured bone variables.   Fisher‟s t-tests (LSD) were used to 
evaluate differences among the means of the treatment groups.  P<0.05 was 
considered significant.  Statistical analyses were performed using SigmaStat 3.1 
statistical software program (Systat Software Inc., San Jose, CA).  Different 
letters a, b, c indicate significant differences at P<0.05 with aging.  Different 
letters w, x, y, z indicate significant differences at P<0.05 due to resveratrol 
supplementation. 
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5.0. RESULTS  
5.1. Final Body Mass of AMB male rats 
In study 1, final body weight was higher (P<0.001) in old compared to 
mature male rats.  Resveratrol supplementation had no effect on the final body 
mass of old or mature male rats (Fig 5). 
 
5.2. Bone Morphometry in AMB male rats 
In study 1, femur length (P<0.001), width (P<0.001), depth (P<0.001), 
and wet weight (P<0.001) were greater in old compared to mature male rats.  
Similarly, tibia length (P<0.001), width (P<0.001), depth (P<0.001), and wet 
weight (P<0.001) were greater in old compared to mature male rats (Table 1).  
Resveratrol supplementation had no effect on bone morphometry, except mature 
male rats provided resveratrol had increased tibia length (P=0.013) compared to 
mature rats provided no resveratrol. A two-way ANOVA indicated an age x 
resveratrol interaction on tibia length (P=0.01) suggesting that resveratrol‟s effect 
was dependent upon age.  Additionally, two-way ANOVA indicated an age x 
resveratrol interaction on tibia width (P=0.012) signifying that resveratrol‟s effect 
was dependent upon age (Table 1).  
 
5.3. Bone Mineralization in AMB male rats 
In study 1, femur BMA (P<0.001), BMC (P=0.003), and ash weight 
(P=0.027) were higher in old compared to mature male rats.  Similarly, tibia 
BMA (P<0.001), BMC (P=0.004), and ash weight (P=0.045) were higher in old 
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compared to mature male rats.  Femur calcium content was increased (P=0.036) 
in old compared to mature rats provided resveratrol.  There were no significant 
differences on femur or tibia BMD and phosphorus content (Table 2).   
When femur BMA was corrected for length, no differences were 
observed: MC=0.53±0.06 cm
2
, MR=0.52±0.05 cm
2
, OC=0.53±0.01 cm
2
, 
OR=0.56±0.02 cm
2
.  Similarly, no differences were observed when femur BMC 
was corrected for length: MC=0.15±0.02 g, MR=0.15±0.02 g, OC=0.15±0.01 g, 
OR=0.16±0.01 g.  Femur ash weight corrected for length resulted in no 
differences: MC=0.14±0.01 g, MR=0.14±0.01 g, OC=0.14±0.01 g, 
OR=0.15±0.01 g.   
When tibia BMA was corrected for length, no differences were observed: 
MC=0.45±0.06 cm
2
, MR=0.42±0.03 cm
2
, OC=0.50±0.03 cm
2
, OR=0.44±0.01 
cm
2
.  Similarly, no differences were observed when tibia BMC was corrected for 
length: MC=0.11±0.01 g, MR=0.10±0.01 g, OC=0.12±0.01 g, OR=0.11±0.01 g.  
Tibia ash weight corrected for length was 0.09±0.01 g for all groups. 
Tibia BMA (P=0.031) and BMC (P=0.034) were decreased in old male 
rats provided resveratrol compared to no resveratrol.  A two-way ANOVA 
indicated an age x resveratrol interaction on tibia BMC (P=0.026).  However, 
resveratrol had no effects when BMA and BMC were corrected for length.  
Resveratrol supplementation had no effect on femur or tibia BMD, ash, and 
phosphorus content in mature or old male rats (Table 2). 
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5.4. Bone Architecture in AMB male rats 
In study 1, femur BV/TV (P<0.001), TbN (P<0.001), and CONN 
(P<0.001) were decreased and TbSp (P<0.001) and SMI (P=0.003) were 
increased in old compared to mature male.  No differences were observed in 
femur TbTH.  Tibia BV/TV (P<0.001), TbN (P<0.001), and CONN (P<0.001) 
were decreased and TbTH (P<0.001), TbSp (P<0.001) and SMI (P<0.001) were 
increased in old compared to mature male rats (Table 3). 
Resveratrol supplementation increased tibia TbTH (P=0.018) in old male 
rats.  Additionally, two-way ANOVA indicated an age x resveratrol interaction on 
tibia TbTH (P=0.037) signifying that resveratrol‟s effect was dependent upon age 
There were no other significant effects of resveratrol supplementation on femur 
and tibia bone architecture measurements in mature or old male rats (Table 3). 
 
5.5. Bone Biomechanics in AMB male rats 
In study 1, femur peak force (P<0.001) and ultimate stiffness (P=0.034) 
and tibia peak force (P=0.005) and ultimate stiffness (P=0.047) were greater in 
old compared to mature male rats.  No significant differences were observed in 
femur or tibia bending failure energy and UBS.  Femur (P=0.002) and tibia 
Young‟s modulus (P=0.034) were decreased in old compared to mature male rats 
(Table 4).  Resveratrol supplementation had no effect on bone strength 
measurements in mature or old male rats (Table 4). 
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5.6. Plasma Clinical Markers in AMB male rats 
In study 1, plasma phosphorus (P<0.001) and ALP (P<0.001) were 
decreased in old compared to mature male rats.  There was no effect on total 
antioxidant capacity; however, plasma TBARS was decreased (P<0.001) in old 
compared to mature male rats.  Plasma CRP were increased (P<0.001) in old 
compared to mature male rats (Table 5).  Providing resveratrol to either mature or 
old male rats had no significant effects on plasma CRP, total antioxidant capacity, 
TBARS, calcium, phosphorus, or ALP (Table 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Final Body Mass of mature and old ambulatory male rats provided 
resveratrol or no resveratrol.  Values are expressed as the mean SEM of n=6-
7. Different letters a, b, within the same column indicate significant differences 
at P<0.05 due to aging by two-way ANOVA followed by Tukey‟s test.  
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§
Values are expressed as the mean SEM of n=12-14 bones/group. Different letters a, b, within the same column indicate 
significant differences at P<0.05 due to aging by two-way ANOVA followed by Tukey‟s test. Different letters x, y, within the 
same column indicate significant differences at P<0.05 due to resveratrol supplementation by two-way ANOVA followed by 
Tukey‟s test.    
Table 1. Bone morphometry of  old and mature ambulatory male rats provided resveratrol or no resveratrol
§
 
Treatment Length (cm) Width (mm) Depth (mm) Wet Weight (g) 
Femur     
MC 3.67±0.03
 b
 5.54±0.07
 b
 3.62±0.05
 b
 0.97±0.02
 b
 
MR 3.69±0.03
 b
 5.64±0.08
 b
 3.65±0.07
 b
 1.04±0.03
 b
 
OC 3.98±0.08
 a
 6.21±0.07
 a
 4.19±0.04
 a
 1.23±0.03
 a
 
OR 3.83±0.02
 ab
 6.30±0.06
 a
 4.21±0.04
 a
 1.19±0.02
 a
 
     
Tibia     
MC 4.09±0.09
 b, z
 4.35±0.03
 b, y
 2.99±0.06
 b
 0.74±0.02
 b
 
MR 4.25±0.03
 ab, y
 4.50±0.06
 b, y
 3.06±0.07
 b
 0.75±0.02
 b
 
OC 4.40±0.02
 a, x 
 4.98±0.05
 a, x
 3.37±0.05
 a
 0.85±0.03
 a
 
OR 4.32±0.02
 a, x 
 4.83±0.07
 a, x 
 3.31±0.06
 a
 0.79±0.02
 ab
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Table 2. Femur and tibia bone mineral area, density, and content in mature and old ambulatory male rats provided resveratrol
  or no resveratrol
§
 
Treatment BMA (cm
2
) BMD (mg/cm
2
) BMC (g)  Ash Weight (g) Ca (mg/g bone) P (mg/g bone) 
Femur       
MC 2.11±0.04
 b
 0.28±0.004 0.60±0.01
 b
 0.50±0.01
 b
 193.88±10.15
 ab
 90.98±3.74 
MR 2.19±0.06
 b
 0.29±0.005 0.63±0.03
 ab
 0.53±0.01
 b
 173.66±16.24
 b
 88.39±3.84 
OC 2.44±0.05
 a
 0.28±0.004 0.68±0.02
 a
 0.68±0.11
 a
 176.30±7.23
 ab
 83.20±2.63 
OR 2.39±0.03
 a
 0.28±0.003 0.67±0.01
 a
 0.57±0.01
 a
 212.84±14.70
 a
 94.63±5.35 
       
Tibia       
MC 1.81±0.03
 b, y
 0.23±0.002 0.42±0.01
 b, z
 0.37±0.01
 b 
 166.31±24.06 80.74±9.65 
MR 1.80±0.05
 b, xy
 0.24±0.004 0.44±0.02
 b, z
 0.38±0.01
 b
 217.28±5.92 91.21±10.07 
OC 2.07±0.06
 a, w
 0.24±0.003 0.49±0.01
 a, x
 0.50±0.08
 a
 167.95±24.61 85.38±17.11 
OR 1.90±0.02
 b, x
 0.24±0.002 0.45±0.01
 a, y
 0.41±0.01
 a
 202.45±11.61 86.44±10.63 
 
§
Values are expressed as the mean SEM of n=6-7 bones/group. Different letters a, b, within the same column indicate 
significant differences at P<0.05 with aging by two-way ANOVA followed by Tukey‟s test. Different letters x, y, within the 
same column indicate significant differences at P<0.05 with resveratrol supplementation by two-way ANOVA followed by 
Tukey‟s test. 
BMA=Bone mineral area, BMC= Bone mineral content, BMD= Bone mineral density, Ca=calcium, P=phosphorus.
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§
Values are expressed as the mean SEM of n=6-7 bones/group. Different letters a, b, within the same column indicate 
significant differences at P<0.05 with aging by two-way ANOVA followed by Tukey‟s test. Different letters x, y, within the 
same column indicate significant differences at P<0.05 with resveratrol supplementation by two-way ANOVA followed by 
Tukey‟s test.     
BV/TV=Trabecular bone volume per unit of total volume, TbN=Trabecular number, TbTh=Trabecular thickness, 
CONN=Connectivity, TbSP=Trabecular separation, SMI=Structure model index, 
Table 3.  Femur and tibia trabecular bone architecture in mature and old ambulatory male rats provided resveratrol or no  
  resveratrol
§
 
Treatment BV/TV  TbN (per mm) TbTH (μm) CONN TbSp (per μm) SMI 
Femur       
MC 0.26±0.02
 a
 4.25±0.37
 a
 0.08±0.002 91.89±13.83
 a
 0.24±0.02
 b
 1.13±0.10
 b
 
MR 0.26±0.01
 a
 4.32±0.09
 a
 0.08±0.002 82.51±8.74
 a
 0.25±0.02
 b
 1.31±0.08
 b
 
OC 0.09±0.01
 b
 1.94±0.05
 b
 0.08±0.003 13.63±0.85
 b
 0.52±0.01
 a
 1.85±0.06
 a
 
OR 0.10±0.01
 b
 1.97±0.06
 b
 0.08±0.002 14.08±1.13
 b
 0.51±0.02
 a
 1.76±0.07
 a
 
       
Tibia       
MC 0.32±0.03
 a
 4.43±0.38
 a
 0.09±0.003
 b, z
 90.88±16.76
 a
 0.21±0.02
 b
 0.88±0.19
 b
 
MR 0.30±0.01
 a
 4.17±0.19
 a
 0.09±0.006
 b, z
 79.00±8.94
 a
 0.22±0.01
 b
 1.05±0.04
 b
 
OC 0.12±0.01
 b
 2.01±0.06
 b
 0.10±0.004
 a, y
   6.89±0.79
 b
 0.48±0.02
 a
 1.97±0.09
 a
 
OR 0.13±0.01
 b
 1.95±0.05
 b
 0.11±0.010
 a, x
 10.05±0.87
 b
 0.49±0.01
 a
 2.09±0.10
 a
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§
Values are expressed as the mean SEM of n=12-14 bones/group. Different letters a, b, within the same column indicate 
significant differences at P<0.05 with aging by two-way ANOVA followed by Tukey‟s test.  
Table 4. Biomechanical measurements of bone strength in mature and old ambulatory male rats provided resveratrol or no 
  resveratrol
§
 
Treatment Peak Force  
(N) 
Ultimate Stiffness  
(N/s) 
Bending Failure 
Energy (N.s) 
Ultimate Bending 
Stress (N/mm
2
) 
Young‟s Modulus 
(N/mm
2
) 
Femur      
MC 194.15±7.27
 b
 488.99±36.02
 b
 5.52±0.68 66.00±7.58
 
 574.90±46.56
 a
 
MR 194.57±6.28
 b
 473.33±32.40
 b
 5.82±0.71 72.09±2.50
 
 528.75±47.27
 a
 
OC 244.68±13.62
 a
 539.07±30.55
 a
 5.57±0.43 70.26±4.30
 
 415.53±26.22
 b
 
OR 228.26±5.36
 a
 571.31±34.84
 a
 5.06±0.30 64.04±2.96
 
 424.34±29.40
 b
 
      
Tibia      
MC 137.53±6.10
 b
 331.11±21.72
 b
 4.06±0.48 115.15±15.96 822.98±55.30
 a
 
MR 135.53±5.34
 b
 312.66±32.08
 b
 3.74±0.47 127.69±14.31 762.38±63.96
 a
 
OC 170.52±13.41
 a
 439.39±55.00
 a
 3.64±0.46 112.38±14.64 541.93±132.78
 b
 
OR 165.50±14.78
 a
 376.31±51.78
 a
 4.75±1.16 119.80±19.20 656.22±91.84
 b
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§
Values are expressed as the mean SE of n=6-7/group. Different letters a, b, within the same column indicate significant 
differences at P<0.05 with aging by two-way ANOVA followed by Tukey‟s test. Different letters x, y, within the same column 
indicate significant differences at P<0.05 with resveratrol supplementation by two-way ANOVA followed by Tukey‟s test.     
Ca=calcium, P=Phosphorus, ALP=Alkaline phosphatase, TBARS= Thiobarbituric acid reactive substances, CRP=C-reactive 
protein 
 
Table 5. Plasma measurements of bone formation, inflammation, and oxidative stress in mature and old ambulatory male rats 
  provided resveratrol or no resveratrol
§
 
Treatment Ca 
(mg/dL) 
P 
(mg/dL) 
ALP 
(U/L) 
Total Antioxidants 
(mM/Trolox) 
TBARS 
(μM MDA) 
CRP 
(mg/mL) 
MC 12.86±0.50 11.66±1.00
 a
 261.86±22.12
 a
 2.44±0.43 5.63±0.21
 a
 0.45±0.18
 b
 
MR 12.06±0.54 10.31±0.51
 a
 264.86±11.17
 a
 2.97±0.79 6.12±0.19
 a
 0.41±0.06
 b
 
OC 11.23±1.03   6.86±0.58
 b
 185.57±11.30
 b
 2.55±0.42 4.43±0.55
 b
 3.47±0.72
 a
 
OR 11.07±0.50   7.27±0.19
 b
 174.86±15.09
 b
 2.61±0.67 4.29±0.48
 b
 2.33±0.41
 a
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5.7. Final Body Mass of HLS male rats 
In study 2, final body weight (P<0.001) was higher in old compared to 
mature HLS male rats.  Resveratrol supplementation had no effect on final body 
mass in old or mature HLS male rats (Fig 7). 
 
5.8. Bone Morphometry in HLS male rats 
 In study 2, femur length (P=0.033), width (P<0.001), depth (P<0.001), 
and wet weight (P<0.001) were higher in old compared to mature male rats.  
Similarly, tibia length (P<0.001), width (P<0.001), depth (P=0.025), and wet 
weight (P=0.004) were higher in old compared to mature HLS male rats.  
Providing resveratrol had no significant effects on femur or tibia morphometry 
(Table 6). 
 
5.9. Bone Mineralization in HLS male rats 
In Study 2, femur BMD (P=0.033) decreased in old compared to mature 
male rats.  Tibia BMA (P=0.004) increased in old compared to mature male rats.  
Tibia BMD decreased (P=0.036) in old compared to mature male rats.  No 
differences were observed when tibia BMA was corrected for length, 
MHC=0.44±0.01, MHR=0.42±0.03, OHC=0.42±0.04, OHR=0.44±0.03. No aging 
effects were observed in other bone mineralization measurements in HLS male 
rats.   
Femur BMA was increased (P=0.031) in old rats provided resveratrol 
compared to old rats provided no resveratrol.  However, when BMA was 
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corrected for length, no effect of resveratrol supplementation was observed.  In 
mature rats, resveratrol supplementation decreased tibia calcium (P=0.018) and 
phosphorus (P=0.024) content compared to male rats provided no resveratrol 
(Table 7).  Resveratrol supplementation had no significant effect on other 
measurements of bone mineralization in mature or old HLS male rats. 
 
5.10. Bone Architecture in HLS male rats 
In study 2, femur and tibia BV/TV (P<0.001), TbN (P<0.001), and 
CONN (P<0.001) decreased and TbSp (P<0.001) and SMI (P<0.001) increased 
in old compared to mature male rats.  No differences were seen in femur TbTH 
between mature and old male rats. Tibia TbTH was increased (P=0.003) in old 
compared to mature rats provided resveratrol (Table 8). Resveratrol 
supplementation had no significant effect on other femur and tibia bone 
architecture measurements in mature or old HLS male rats. 
 
5.11. Bone Biomechanics in HLS male rats 
In study 2, femur UBS (P<0.001) and Young‟s modulus (P=0.032) were 
decreased in old compared to mature HLS male rats.  Tibia peak force (P=0.049) 
and femur ultimate stiffness (P<0.001) were increased in old compared to mature 
rats.  There were no significant effects of aging on bending failure energy. 
Resveratrol supplementation had no significant effect on femur and tibia strength 
measurements in HLS mature or old rats (Table 9). 
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Figure 7. Final Body Mass of mature and old hindlimb suspended rats provided 
resveratrol or no resveratrol.  Values are expressed as the mean ±SEM of n=6-7.  
Different letters a, b, within the same column indicate significant differences at 
P<0.05 due to aging by two-way ANOVA followed by Tukey‟s test. 
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5.12. Plasma Clinical Markers in HLS male rats 
In study 2, plasma calcium (P=0.033), phosphorus (P<0.001), and ALP 
(P=0.009) were decreased in old compared to mature male rats.  There was no 
effect on total antioxidant capacity; however, plasma TBARS (P=0.036) were 
decreased in old compared to mature male rats.  Plasma CRP was increased 
(P=0.015) in old male rats compared to mature male rats 
Resveratrol supplementation had no effect on plasma calcium, 
phosphorus, or ALP. Resveratrol had no effect on plasma total antioxidant 
capacity.  However, plasma TBARS increased (P=0.036) in mature male rats 
provided resveratrol compared to no resveratrol.  In old male rats, resveratrol 
supplementation decreased (P=0.042) plasma TBARS compared to rats provided 
no resveratrol (Table 10).  A two-way ANOVA indicated an age x resveratrol 
interaction (P=0.005) on plasma TBARS.  (Table 10).   
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§
Values are expressed as the mean SEM of n=12-14 bones/group. Different letters a, b, within the same column indicate 
significant differences at P<0.05 with aging by two-way ANOVA followed by Tukey‟s test. Different letters x, y, within the 
same column indicate significant differences at P<0.05 with resveratrol supplementation by two-way ANOVA followed by 
Tukey‟s test.    
Table 6. Bone morphometry in old and mature hindlimb suspended male rats provided resveratrol or no resveratrol
§
 
Treatment Length (cm) Width (mm) Depth (mm) Wet Weight (g) 
Femur     
MHC 3.72±0.03
 b
 5.49±0.08
 b
 3.61±0.06
 b
 1.12±0.07
 b
 
MHR 3.68±0.03
 b
 5.56±0.08
 b
 3.59±0.07
 b
 1.02±0.03
 b
 
OHC 3.84±0.07
 a
 6.20±0.05
 a
 4.25±0.07
 a
 1.10±0.03
 a
 
OHR 3.84±0.02
 a 
 6.24±0.06
 a
 4.15±0.06
 a
 1.17±0.02
 a
 
     
Tibia     
MHC 4.23±0.02
 b
 4.48±0.06
 b
 3.09±0.07
 b 
 0.75±0.02
 b
 
MHR 4.19±0.03
 b
 4.36±0.06
 b
 3.13±0.07
 b
 0.73±0.02
 b
 
OHC 4.32±0.03
 a
 4.79±0.05
 a
 3.29±0.07
 a 
 0.79±0.02
 a
 
OHR 4.28±0.07
 a
 4.84±0.04
 a
 3.23±0.04
 a
 0.81±0.02
 a
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Table 7. Femur and tibia bone mineral area, density, and content in  old and mature hindlimb suspended  male rats provided 
  resveratrol or no resveratrol
§
 
Treatment BMA (cm
2
) BMD (mg/cm
2
) BMC (g)  Ash Weight (g) Ca (mg/g bone) P (mg/g bone) 
Femur       
MHC 2.18±0.05
 b
 0.29±0.008
 a 
 0.62±0.03 0.52±0.02
 
 186.62±4.81
 
 89.65±1.82 
MHR 2.16±0.07
 b
 0.28±0.007
 a 
 0.60±0.03 0.51±0.02
 
 182.16±16.50
 
 85.49±7.56 
OHC 2.29±0.06
 ab
 0.26±0.007
 b
  
 
 0.60±0.03 0.51±0.01
 
 181.54±3.16
 
 80.33±1.66 
OHR 2.40±0.03
 a 
 0.27±0.003
 b
 0.65±0.01 0.53±0.01
 
 192.49±7.39
 
 86.84±2.69 
       
Tibia       
MHC 1.78±0.03
 b, z
 0.25±0.005
 a
 0.44±0.02 0.39±0.01 211.91±4.78
 x
 89.34±9.64
 x
 
MHR 1.77±0.05
 b, z
 0.24±0.005
 ab
 0.42±0.02 0.38±0.01 185.84±10.53
 y
 79.20±9.47
 y
 
OHC 1.88±0.05
 a, y 
 0.23±0.004
 b
 0.43±0.02 0.39±0.01 194.86±3.35
 z 
 80.08±8.28
 z
 
OHR 1.94±0.03
 a, x 
0.24±0.004
 b
 0.46±0.01 0.41±0.01 205.83±3.52
 z
 84.80±9.19
 z
 
 
§
Values are expressed as the mean SEM of n=6-7 bones/group. Different letters a, b, within the same column indicate 
significant differences at P<0.05 with aging by two-way ANOVA followed by Tukey‟s test. Different letters x, y, within the 
same column indicate significant differences at P<0.05 with resveratrol supplementation by two-way ANOVA followed by 
Tukey‟s test. 
Ca=calcium, P=phosphorus, BMA=Bone mineral area, BMC= Bone mineral content, BMD= Bone mineral density
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§
Values are expressed as the mean SEM of n=6-7 bones/group. Different letters a, b, within the same column indicate 
significant differences at P<0.05 with aging by two-way ANOVA followed by Tukey‟s test. Different letters x, y, within the 
same column indicate significant differences at P<0.05 with resveratrol supplementation by two-way ANOVA followed by 
Tukey‟s test.     
BV/TV=Trabecular bone volume per unit of total volume, TbN=Trabecular number, TbTh=Trabecular thickness, 
CONN=Connectivity, TbSP=Trabecular separation, SMI=Structure model index,  
Table 8.  Femur and tibia trabecular bone architecture in old and mature hindlimb suspended male rats provided resveratrol or 
  no resveratrol
§
 
Treatment BV/TV  TbN (per mm) TbTH (μm) CONN TbSp (per μm) SMI 
Femur   
 
    
MHC 0.22±0.02
 a
 4.01±0.29
 a
 0.079±0.004 77.88±9.11
 a
 0.25±0.02
 b
 1.49±0.19
 b
 
MHR 0.20±0.01
 a
 3.91±0.23
 a
 0.074±0.004 76.86±8.89
 a
 0.26±0.02
 b
 1.63±0.13
 ab
 
OHC 0.06±0.01
 b
 1.73±0.09
 b
 0.069±0.002 10.05±1.60
 b
 0.59±0.03
 a
 2.13±0.13
 a
 
OHR 0.08±0.01
 b
 1.90±0.05
 b
 0.074±0.003 12.48±1.16
 b
 0.53±0.01
 a
 1.86±0.11
 ab
 
       
Tibia       
MHC 0.29±0.01
 a
 4.26±0.29
 a
 0.090±0.004
 ab
 81.59±13.69
 a
 0.21±0.01
 b
 1.18±0.13
 b
 
MHR 0.28±0.02
 a
 4.32±0.22
 a
 0.085±0.003
 b
 84.40±9.39
 a
 0.21±0.01
 b
 1.26±0.10
 b
 
OHC 0.09±0.01
 b
 1.81±0.05
 b
 0.095±0.003
 ab
   6.89±0.79
 b
 0.55±0.02
 a
 2.29±0.18
 a
 
OHR 0.12±0.01
 b
 1.96±0.06
 b
 0.101±0.002
 a
   9.33±0.73
 b
 0.49±0.02
 a
 2.18±0.07
 a
 
44 
 
 
 
§
Values are expressed as the mean SEM of n=12-14 bones/group. Different letters a, b, within the same column indicate 
significant differences at P<0.05 with aging by two-way ANOVA followed by Tukey‟s test. 
Table 9. Biomechanical measurements of bone strength in old and mature hindlimb suspended male rats provided resveratrol 
  or no resveratrol supplementation. 
§
 
Treatment Peak Force  
(N) 
Ultimate Stiffness  
(N/s) 
Bending Failure 
Energy (N.s) 
Ultimate Bending 
Stress (N/mm
2
) 
Young‟s Modulus 
(N/mm
2
) 
Femur      
MHC 220.67±12.49 471.70±42.32
 b
 5.74±0.48 85.23±4.04
 a
 548.78±39.90
 a
 
MHR 206.85±10.91 469.94±28.54
 b
 4.71±0.75 78.59±3.28
 a
 542.12±38.20
 a
 
OHC 190.65±9.29 613.12±41.91
 a
 4.10±0.75 54.57±2.96
 b
 470.06±29.32
 b
 
OHR 217.36±12.57 604.37±42.41
 a
 4.61±0.53 62.06±3.35
 b 
 463.69±33.87
 b
 
      
Tibia      
MHC 146.07±5.10
 b
 352.25±31.10 4.32±0.64 119.37±9.70 791.98±63.10 
MHR 134.14±6.89
 b
 311.22±29.86 3.85±0.48 112.61±9.74 737.15±59.44 
OHC 174.38±19.79
 a 
 398.61±41.64 4.49±0.87 133.41±22.80 726.17±81.35 
OHR 160.18±16.27
 a 
 372.71±42.58 5.40±1.21 124.50±18.81 661.88±73.98 
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§
Values are expressed as the mean SEM of n=6-7/group. Different letters a, b, within the same column indicate significant 
differences at P<0.05 with aging by two-way ANOVA followed by Tukey‟s test. Different letters x, y, within the same column 
indicate significant differences at P<0.05 with resveratrol supplementation by two-way ANOVA followed by Tukey‟s test.     
Ca=calcium, P=phosphorus, ALP=Alkaline phosphatase, TBARS= Thiobarbituric acid reactive substances, CRP=C-reactive 
protein 
Table 10. Plasma measurements of bone formation, inflammation, and oxidative stress in mature and old hindlimb suspended
  male rats provided resveratrol or no resveratrol supplementation
§
 
Treatment Ca 
(mg/dL) 
P 
(mg/dL) 
ALP 
(U/L) 
Total Antioxidant 
(mM/Trolox) 
TBARS 
(μM MDA) 
CRP 
(mg/mL) 
MHC 13.40±6.27
 a
 10.16±0.33
 a
 203.29±15.87
 a
 1.22±0.46 4.51±0.05
 a, x
 0.51±0.15
 b
 
MHR 13.21±0.82
 a
 11.21±0.72
 a
 221.29±20.64
 a
 2.02±0.76 4.99±0.18
 a, w
 1.14±0.53
 b
 
OHC 11.31±1.09
 b
   6.71±0.41
 b
 169.43±20.19
 b
 1.33±0.50 4.03±0.20
 b, y
 3.46±0.49
 a
 
OHR 11.53±0.72
 b
   7.19±0.43
 b
 160.00±6.96
 b
 1.38±0.52 3.56±0.13
 b, z
 2.39±0.71
 a
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6.0 DISCUSSION 
In Study 1, loss of trabecular bone in the femur and tibia was observed in 
aging AMB rats indicated by decreased bone volume, trabecular number, and 
connectivity with increased trabecular separation and SMI.  In old rats, reduced 
bone formation was indicated by decreased plasma ALP concentration.  ALP is 
associated with bone matrix synthesis prior to mineralization (Cao et al., 2009).  
Femur and tibia BMC and ash were higher in old compared to mature rats.  This 
was likely due to the greater bone size of the old compared to mature rats.  BMC 
and bone ash corrected for bone size showed that bone mineralization was not 
decreased in aged 32 month old male rats.  In rats, peak femur and tibia BMD 
tend to occur between the ages of 6 and 21 months (Iida and Fukuda, 2002).  
Body weight continues to increase until approximately 12 months of age, and 
long bones continue to increase in length and weight until old age in rats due to 
non-fusing of the epiphyses in rats (Iida and Fukuda, 2002).  In our study, male 
Fisher Brown Norway rats continued to grow after age 6 months indicated by 
greater final body mass, femur and tibia length, width, and weight.  Therefore, 
this is important to consider when choosing a rat model to study aging effects on 
bone. 
Bone strength indicated by higher femur and tibia peak force and ultimate 
stiffness in old compared to mature male rats was also due to greater bone size.  
Measuring Young‟s modulus which takes bone size into consideration showed 
that aging decreased femur and tibia bone strength.  Trabecular bone formation 
may be more indicative of biomechanical competence.  Pietschmann et al. (2007) 
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observed that tibia trabecular BMD decreased by as much as 48% between ages 5 
and 23 month old in male Sprague-Dawley rats.  The authors attributed decreased 
bone mass to removal of trabecular bone elements.  Legrand et al. (2000) 
observed that trabecular architecture is directly related to vertebral fracture in 
middle-aged men diagnosed with severe osteopenia.  Differences in fractures 
were observed even in men with identical cortical BMD.  In our study, 
unfavorable bone architecture and decreased strength was observed in the absence 
of bone mineral loss. 
To attenuate age-related bone loss, resveratrol was supplemented at 12.5 
mg·kg bw
-1
·d
-1
.  Other studies have used doses of 10 to 50 mg·kg bw
-1
·d
-1
 (Lin et 
al., 2005; Liu, et al., 2005; Mizutani et al., 2000; Yoshida et al. 2007).  In the 
current study, resveratrol supplementation had no effect on final body weight or 
femur morphometry.  However, tibia length was increased in mature AMB rats.  
Resveratrol supplements of 20 mg·kg bw
-1
·d
-1
 had no effects on body weight or 
long bone growth in young male Sprague-Dawley rats (Juan et al., 2002).  
Yoshida et al. (2007) observed an increase in tibia length after 2 weeks of 
supplemental resveratrol dose of 50 mg·kg bw
-1
·d
-1
 of resveratrol to young female 
rats. 
In old rats, resveratrol supplementation increased tibia trabecular thickness 
while having no effects on cortical mineralization in AMB male rats.  Most bone 
effects were observed in the tibia.  This may be due to the rapid growth of the 
tibia compared to the femur (Davenport, 1933).  In the current study, reduced 
BMC in old rats may be due to resveratrol acting as a pro-oxidant.  In vitro, 
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oxidized lipids inhibit osteoblast differentiation (Parhami et al., 1997).  However, 
in our study resveratrol supplementation had no effect on plasma TBARS in old 
rats indicating resveratrol did not act as a lipid pro-oxidant.      
Turrens et al. (1997) found no effects of resveratrol on serum TBARS in 
rats at doses of 20 and 40 mg·kg bw
-1
·d
-1
 for 21 days.  In our study, plasma 
TBARS was lower in old compared to mature rats; however, inflammation was 
greater in old rats indicated by higher plasma CRP compared to mature rats.  Ding 
et al. (2007) reported that high-sensitivity (hs)-CRP was adversely associated with 
total body BMD in men and women (between age 52-78). Resveratrol 
supplementation of young female rats has been shown to protect against 
ovariectomy-induced loss of femur BMD after 13 weeks of 45 mg·kg bw
-1
·d
-1
 
(Lin et al., 2005) and after 12 weeks of 0.7 mg·kg bw
-1
·d
-1
 (Liu, et al., 2005).  
Therefore, a longer duration of resveratrol supplementation may be required to 
attenuate bone mineral loss in aging male rats. 
In Study 1, the only significant effect of resveratrol on age-related bone 
loss was the attenuation of loss of trabecular bone.  In general, trabecular bone is 
more responsive than cortical bone during aging because trabecular bone is more 
actively remodeled due to the larger surface to volume ratio (Morgan et al., 2008).  
We were also interested in the potential effect of resveratrol on cortical bone.  
HLS induces significant bone loss.  Allen and Bloomfield (2002) observed a 
greater impact of HLS on cortical than on trabecular bone in age 6 month old 
male rats.  In addition, aging individuals have higher incidence of mechanical 
unloading due to inactivity and/or bed rest.  Therefore, in Study 2 rats were HLS. 
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HLS of aging rats resulted in loss of femur and tibia trabecular bone 
indicated by decreased bone volume, trabecular number, and connectivity with 
increased trabecular separation and SMI.  HLS of old rats also decreased BMD, 
but had no effect on bone growth.  Measurements such as UBS and Young‟s 
modulus, that take bone size into account showed decreased femur strength in old 
compared to mature rats.  Similarly, Smith et al. (1975) reported increased 
fracture risk with age-related loss of bone mineral. 
Decreased lipid peroxidation indicated by reduced plasma TBARS was 
observed in old rats provided resveratrol.    However, plasma TBARS was higher 
in mature rats provided resveratrol compared to no resveratrol.  Therefore, an 
increase in lipid peroxidation may have contributed to decreased tibia calcium and 
phosphorus content in mature rats provided resveratrol.   
In mature HLS rats, resveratrol supplementation reduced tibia calcium and 
phosphorus content.  In contrast, Liu et al. (2005) reported that resveratrol 
protected bone calcium content in ovariectomy rats.  Resveratrol‟s protective role 
in bones may be sex- or age-specific.  Considering the pleiotropic effects of 
resveratrol, it is not surprising that there are a variety of outcomes.  To our 
knowledge no other studies have investigated resveratrol‟s effects on bone in 
aging male rats. 
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7.0 SUMMARY AND CONCLUSIONS 
In summary, resveratrol supplementation appeared to have age-specific 
effects.  Therefore, it is important to consider the rat strain when studying age-
related bone loss.  Wang et al. (2001) reported that bone loss began at age nine 
months in male Sprague-Dawley rats.  In our study bone growth continued at age 
32 months.  Trabecular but not cortical bone was lost in aging male Fischer 
Brown Norway rats.   
Resveratrol supplementation attenuated loss of trabecular bone in old 
AMB rats, but increased bone mineral loss in mature HLS rats.  This may have 
occurred because resveratrol supplementation was observed to decrease oxidation 
in old but not mature HLS male rats.  Mature rats subjected to HLS and provided 
resveratrol supplementation had increased oxidation and reduced tibia Ca and P 
content.  Based on the study results, resveratrol supplementation is currently not 
recommended for the prevention of age-related bone loss. 
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